Experts discuss the biological mechanisms of resistance in gastrointestinal stromal tumors (GIST), differentiating between primary and secondary resistance, and explore how tumor heterogeneity evolves throughout treatment, with implications for […]

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Experts discuss optimizing TKI selection and sequencing strategies for advanced gastrointestinal stromal tumors (GIST) beyond first-line therapy, focusing on the latest clinical data, molecular characterization, and insights from recent trials to […]

The EMA’s CHMP recommended the approval of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer.

Xiuning Le, MD, PhD, discusses data from the HARMONi-2 trial of ivonescimab vs pembrolizumab in PD-L1–positive NSCLC.

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem […]

Experts discuss where chimeric antigen receptor (CAR) T-cell therapy currently fits in the treatment paradigm, highlighting the patient factors and disease characteristics that influence its use in clinical decision-making.

Panelists discuss how treating patients with advanced endometrial cancer (EC) who progress after immune-oncology (IO)-chemotherapy involves reassessing tumor biomarkers, considering alternative immunotherapies or targeted treatments, and […]

Panelists discuss how the integration of immunotherapy, particularly immune checkpoint inhibitors (ICIs) and combination therapies, is transforming the treatment landscape of advanced endometrial cancer (EC), with a focus on biomarker-driven […]

Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.

Panelists discuss how, if the MARIPOSA trial shows an overall survival advantage exceeding 1 year, the amivantamab-lazertinib combination may see increased frontline use. Subsequent therapy options could include chemotherapy, targeted therapies […]

Panelists discuss how the FLAURA, FLAURA2, and MARIPOSA trials have reshaped first-line therapy for EGFR-mutant non–small cell lung cancer. FLAURA established osimertinib as superior to first-generation tyrosine kinase inhibitors. FLAURA2 showed […]

Panelists discuss how the first-line treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC) primarily includes EGFR tyrosine kinase inhibitors, with osimertinib as the preferred monotherapy due to its efficacy and central nervous […]

Panelists discuss how medical professionals consider continuing osimertinib with second-line and subsequent therapies based on disease progression, resistance mechanisms, and patient response. It may be combined with other agents or switched […]

Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Jeffrey Zonder, MD, emphasizes the importance of identifying MGUS and evaluating nonspecific symptoms to improve the detection of multiple myeloma.

Tashanna K. Myers, MD, discusses HRQOL findings in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine in MIRASOL.

Chunyan Lan, MD, PhD, discusses data with cadonilimab plus lenvatinib in advanced endometrial cancer, as well as next steps for evaluating the combination.

Matthew Galsky, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with muscle-invasive bladder cancer.

The FDA approved perioperative durvalumab plus chemotherapy for muscle-invasive bladder cancer.